BRPI0108394B8 - inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos - Google Patents

inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos

Info

Publication number
BRPI0108394B8
BRPI0108394B8 BRPI0108394A BRPI0108394B8 BR PI0108394 B8 BRPI0108394 B8 BR PI0108394B8 BR PI0108394 A BRPI0108394 A BR PI0108394A BR PI0108394 B8 BRPI0108394 B8 BR PI0108394B8
Authority
BR
Brazil
Prior art keywords
protein kinase
substituted pyrrole
kinase inhibitors
salts
pharmaceutical compositions
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
S Nematalla Assad
Chen Wei Chung
Liang Congxin
Sun Li
Hawley Michael
Cho Tang Peng
Shirazian Shahrzad
A Miller Todd
Vojkovsky Tomas
Li Xiaoyuan
Original Assignee
Upjohn Co
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27391578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0108394(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co, Sugen Inc filed Critical Upjohn Co
Priority to BRPI0117360A priority Critical patent/BRPI0117360B8/pt
Publication of BR0108394A publication Critical patent/BR0108394A/pt
Publication of BRPI0108394B1 publication Critical patent/BRPI0108394B1/pt
Publication of BRPI0108394B8 publication Critical patent/BRPI0108394B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Polyurethanes Or Polyureas (AREA)
BRPI0108394 2000-02-15 2001-02-15 inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos BRPI0108394B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BRPI0117360A BRPI0117360B8 (pt) 2000-02-15 2001-02-15 inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18271000P 2000-02-15 2000-02-15
US21642200P 2000-07-06 2000-07-06
US24353200P 2000-10-27 2000-10-27
PCT/US2001/004813 WO2001060814A2 (en) 2000-02-15 2001-02-15 Pyrrole substituted 2-indolinone protein kinase inhibitors

Publications (3)

Publication Number Publication Date
BR0108394A BR0108394A (pt) 2004-06-22
BRPI0108394B1 BRPI0108394B1 (pt) 2018-12-11
BRPI0108394B8 true BRPI0108394B8 (pt) 2021-05-25

Family

ID=27391578

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0108394 BRPI0108394B8 (pt) 2000-02-15 2001-02-15 inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
BRPI0117360A BRPI0117360B8 (pt) 2000-02-15 2001-02-15 inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0117360A BRPI0117360B8 (pt) 2000-02-15 2001-02-15 inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos

Country Status (42)

Country Link
US (4) US6573293B2 (enExample)
EP (1) EP1255752B1 (enExample)
JP (1) JP3663382B2 (enExample)
KR (1) KR100713960B1 (enExample)
CN (1) CN1329390C (enExample)
AR (1) AR034118A1 (enExample)
AT (1) ATE369359T1 (enExample)
AU (2) AU2001239770B2 (enExample)
BE (1) BE2010C009I2 (enExample)
BG (1) BG65764B1 (enExample)
BR (2) BRPI0108394B8 (enExample)
CA (1) CA2399358C (enExample)
CO (1) CO5280092A1 (enExample)
CR (2) CR20120007A (enExample)
CY (3) CY1108032T1 (enExample)
CZ (1) CZ303705B6 (enExample)
DE (3) DE60129794T2 (enExample)
DK (1) DK1255752T3 (enExample)
EA (1) EA005996B1 (enExample)
ES (1) ES2290117T3 (enExample)
FR (2) FR08C0002I2 (enExample)
HR (1) HRP20020751B1 (enExample)
HU (1) HU228979B1 (enExample)
IL (1) IL151127A0 (enExample)
IS (1) IS2491B (enExample)
LT (1) LTC1255752I2 (enExample)
LU (2) LU91407I2 (enExample)
ME (1) ME00415B (enExample)
MX (1) MXPA02008021A (enExample)
MY (1) MY130363A (enExample)
NL (2) NL300332I2 (enExample)
NO (4) NO325532B1 (enExample)
NZ (1) NZ520640A (enExample)
PE (1) PE20011083A1 (enExample)
PL (1) PL211834B1 (enExample)
PT (1) PT1255752E (enExample)
RS (1) RS50444B (enExample)
SI (1) SI1255752T1 (enExample)
SK (1) SK287142B6 (enExample)
TW (1) TWI306860B (enExample)
UA (1) UA73976C2 (enExample)
WO (1) WO2001060814A2 (enExample)

Families Citing this family (344)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
DE60045474D1 (de) 1999-01-13 2011-02-17 Univ New York State Res Found Neues verfahren zum erschaffen von proteinkinase-inhibitoren
EP1255752B1 (en) * 2000-02-15 2007-08-08 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
TWI270545B (en) 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
JP2003535847A (ja) 2000-06-02 2003-12-02 スージェン・インコーポレーテッド 蛋白質キナーゼ／ホスファターゼ阻害剤としてのインドリノン誘導体
EP1296975A1 (en) 2000-06-30 2003-04-02 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
MX242553B (es) 2000-10-20 2006-12-06 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
AR035721A1 (es) 2000-12-20 2004-07-07 Sugen Inc Indolinonas 4-aril sustituidas; sus composiciones farmaceuticas y metodo para modular la actividad catalitica de una proteina quinasa
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
JP2004529110A (ja) 2001-03-06 2004-09-24 アストラゼネカ アクチボラグ 脈管損傷活性を有するインドール誘導体
EP1247809A3 (en) * 2001-03-30 2003-12-17 Pfizer Products Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
AU2002303892A1 (en) 2001-05-30 2002-12-09 Jingrong Cui 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
EP1471907B1 (en) * 2001-06-29 2008-07-16 AB Science Use of c-kit inhibitors for treating autoimmune diseases
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
CN100364991C (zh) 2001-08-15 2008-01-30 法玛西雅厄普约翰美国公司 2,4-二甲基-1h-吡咯-3-甲酰胺衍生物的苹果酸盐的晶体、其制备方法和其组合物
WO2003022815A1 (en) * 2001-09-10 2003-03-20 Sugen, Inc. 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
BR0213185A (pt) * 2001-10-10 2004-09-14 Sugen Inc Derivados de 3-[4-(heterociclila substituìda)-pirrol-2-ilmetilideno]2-indolinona como inibidores de cinase
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
US7129225B2 (en) * 2001-10-22 2006-10-31 The Research Foundation Of State University Of New York Protection against and treatment of hearing loss
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
US20030080191A1 (en) * 2001-10-26 2003-05-01 Allen Lubow Method and apparatus for applying bar code information to products during production
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20050131733A1 (en) * 2001-12-17 2005-06-16 Allen Lubow Sealable individual bar coded packets
US7156308B2 (en) * 2001-12-17 2007-01-02 International Barcode Corporation Double-sided bar code doubling as a single bar code
DK1458713T3 (da) 2001-12-27 2005-10-31 Theravance Inc Indolinonderivater anvendelige som proteinkinaseinhibitorer
RU2299209C2 (ru) 2002-02-15 2007-05-20 Фармация Энд Апджон Компани Способ получения производных индолинона
US20040018528A1 (en) * 2002-05-17 2004-01-29 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
ITMI20021620A1 (it) * 2002-07-23 2004-01-23 Novuspharma Spa Composto ad ativita' antitumorale
WO2004016211A2 (en) * 2002-08-08 2004-02-26 Vanderbilt University Pi3k antagonists as radiosensitizers
JP4588447B2 (ja) * 2002-08-09 2010-12-01 セラヴァンス， インコーポレーテッド 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
TW200418836A (en) * 2002-09-10 2004-10-01 Pharmacia Italia Spa Formulations comprising an indolinone compound
AR042042A1 (es) * 2002-11-15 2005-06-08 Sugen Inc Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
US7626031B2 (en) * 2002-11-15 2009-12-01 Symphony Evolution, Inc. Substituted 3-(diarylmethylene)indolin-2-ones and methods of their use
US20040209937A1 (en) * 2003-02-24 2004-10-21 Sugen, Inc. Treatment of excessive osteolysis with indolinone compounds
US7452913B2 (en) * 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
DK2476667T3 (da) 2003-02-26 2014-09-15 Sugen Inc Aminoheteroaryl-forbindelser som proteinkinase-inhibitorer
US7157577B2 (en) * 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
US20040266843A1 (en) * 2003-03-07 2004-12-30 Sugen, Inc. Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
EP1604665B1 (en) * 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10334582A1 (de) * 2003-07-28 2005-02-24 Basf Ag Verfahren zur Herstellung von Maleinsäureanhydrid
WO2005023765A1 (en) * 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Method for catalyzing amidation reactions by the presence of co2
BRPI0415022A (pt) * 2003-10-02 2006-11-28 Pharmacia & Upjohn Co Llc sais e polimorfos de um composto de indolinona substituìda com pirrol
WO2005037235A2 (en) * 2003-10-16 2005-04-28 Imclone Systems Incorporated Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
CA2544186A1 (en) 2003-11-07 2005-05-26 Chiron Corporation Inhibition of fgfr3 and treatment of multiple myeloma with benzimidazole quinolinones
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
BRPI0416994A (pt) * 2003-11-26 2007-02-06 Scripps Research Inst inibidores de proteìna cinase com base em indolinona avançada
EP1699477A2 (en) * 2003-12-11 2006-09-13 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
US20050152943A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
DE602005020465D1 (de) * 2004-08-26 2010-05-20 Pfizer Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
JP4834553B2 (ja) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
CN100432071C (zh) * 2004-11-05 2008-11-12 中国科学院上海药物研究所 取代1h－吲哚－2－酮类化合物及其制备方法和用途
GT200500321A (es) * 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
MX2007011767A (es) * 2005-03-23 2007-10-18 Pfizer Prod Inc Terapia de combinacion de anticuerpo anti-ctla4 e indolinona para el tratamiento del cancer.
AU2006238930B2 (en) 2005-04-26 2010-12-23 Pfizer Inc. P-cadherin antibodies
EP1885355A1 (en) * 2005-05-12 2008-02-13 Pfizer, Inc. Anticancer combination therapy using sunitinib malate
SG177981A1 (en) 2005-05-18 2012-02-28 Array Biopharma Inc 4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
JP2008542289A (ja) 2005-05-23 2008-11-27 ノバルティス アクチエンゲゼルシャフト ４−アミノ−５−フルオロ−３−［６−（４−メチルピペラジン−１イル）−１ｈ−ベンズイミダゾール−２−イル］−１ｈ−キノリン−２−オン乳酸塩の結晶およびその他の形態
KR20080017058A (ko) * 2005-05-26 2008-02-25 더 스크립스 리서치 인스티튜트 향상된 인돌리논계 단백질 키나제 억제제
EP1925941B1 (en) * 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
NZ566774A (en) 2005-09-07 2011-11-25 Pfizer Human monoclonal antibodies to activin receptor-like kinase-1
CA2621569C (en) 2005-09-19 2010-10-19 Pfizer Products Inc. Solid salt forms of a pyrrole substituted 2-indolinone
WO2007052849A1 (ja) 2005-11-07 2007-05-10 Eisai R & D Management Co., Ltd. 血管新生阻害物質とc-kitキナーゼ阻害物質との併用
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
US20080269212A1 (en) * 2005-12-29 2008-10-30 The Scripps Research Institute Amino acid derivatives of indolinone based protein kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CN101007801A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯取代的2－二氢吲哚酮衍生物、其制法与医药上的用途
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
RU2008145225A (ru) 2006-04-19 2010-05-27 Новартис АГ (CH) Соединения индазола и способы ингибирования cd7
KR20090007792A (ko) 2006-05-09 2009-01-20 화이자 프로덕츠 인크. 시클로알킬아미노산 유도체 및 이들의 제약 조성물
EP2036557B1 (en) * 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
DE102006024834B4 (de) * 2006-05-24 2010-07-01 Schebo Biotech Ag Neue Indol-Pyrrol-Derivate und deren Verwendungen
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
WO2008001956A1 (en) * 2006-06-29 2008-01-03 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
EP2040738A1 (en) 2006-07-13 2009-04-01 Zymogenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
BRPI0714665A2 (pt) 2006-08-04 2012-03-13 Takeda Pharmaceutical Company Limited Composto, pró-droga, agente farmacêutico, e, método para a profilaxia ou tratamento do câncer
MX2009001946A (es) * 2006-08-23 2009-03-05 Kudos Pharm Ltd Derivados de 2-metilmorfolin-pirido-, pirazo- y pirimido- pirimidina como inhibidores de mtor.
CN101511793B (zh) * 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
ES2565683T3 (es) 2006-09-15 2016-04-06 Xcovery, Inc. Compuestos inhibidores de quinasa
EP3181580A1 (en) 2006-11-02 2017-06-21 Acceleron Pharma Inc. Alk1 receptor and ligand antagonists and uses thereof
JP4623604B2 (ja) * 2006-11-06 2011-02-02 株式会社セラバリューズ 新規なオキシインドール誘導体
MY146474A (en) 2006-11-06 2012-08-15 Supergen Inc Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
EP2123649B1 (en) 2006-12-04 2012-02-29 Jiangsu Simcere Pharmaceutical R&D Co., Ltd. 3-pyrrolo-cyclohexylene-2-dihydro-indolinone derivatives and uses thereof
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
BRPI0807165A2 (pt) 2007-02-06 2014-05-06 Pfizer Compostos de 2-amino pirimidina
US8044056B2 (en) 2007-03-20 2011-10-25 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US20090042906A1 (en) * 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
WO2008138184A1 (fr) 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
WO2008145398A1 (en) * 2007-06-01 2008-12-04 Pfizer Italia S.R.L. 4-arylpyrrole substituted 2-indoline derivatives active as protein kinase inhibitors
AR066845A1 (es) 2007-06-05 2009-09-16 Takeda Pharmaceutical Derivados de triazolopiridina e imidazopiridina una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
US20090062368A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched sunitinib
PL2197878T3 (pl) * 2007-09-06 2017-01-31 Boston Biomedical, Inc. Kompozycje inhibitorów kinaz oraz ich zastosowanie w leczeniu nowotworów i innych chorób związanych z kinazami
AU2008309383B2 (en) 2007-10-11 2012-04-19 Astrazeneca Ab Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors
EP2218712B1 (en) 2007-11-09 2015-07-01 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
EP2253629A1 (en) * 2007-11-21 2010-11-24 Teva Pharmaceutical Industries Ltd. Polymorphs of racemic sunitinib malate, compositions containing them and preparation thereof
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
WO2009074862A1 (en) * 2007-12-12 2009-06-18 Medichem S.A. Polymorphic forms of a 3-pyrrole substituted 2-indolinone
JP5421925B2 (ja) 2007-12-19 2014-02-19 ジェネンテック， インコーポレイテッド ５−アニリノイミダゾピリジン及び使用の方法
EA201000947A1 (ru) 2007-12-20 2011-02-28 Новартис Аг Производные тиазола, применимые в качестве ингибиторов киназы pi3
EP2220092B1 (en) 2007-12-21 2012-06-06 Genentech, Inc. Azaindolizines and methods of use
JP5399926B2 (ja) * 2008-01-29 2014-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管阻害物質とタキサンとの併用
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
CA2713112A1 (en) * 2008-02-13 2009-08-20 Ratiopharm Gmbh Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
CN101255154B (zh) * 2008-02-18 2011-09-07 靳广毅 一种取代的2-吲哚啉酮衍生物和制备方法及其应用
JP2011512396A (ja) * 2008-02-21 2011-04-21 ジェネリクス・（ユーケー）・リミテッド 新規な多形およびその調製方法
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
WO2009124037A1 (en) * 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
WO2009128083A1 (en) * 2008-04-16 2009-10-22 Natco Pharma Limited Novel polymorphic forms of sunitinib base
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
EP2292613B1 (en) * 2008-05-23 2015-09-30 Shanghai Institute of Pharmaceutical Industry Dihydroindolinone derivatives
WO2009154697A2 (en) 2008-05-28 2009-12-23 Massachusetts Institute Of Technology Disc-1 pathway activators in the control of neurogenesis
EP2313371B1 (en) * 2008-06-13 2012-08-15 Medichem, S.A. Process for preparing a 3-pyrrole substituted 2-indolinone malate salt
CA2724310A1 (en) * 2008-06-23 2009-12-30 Natco Pharma Limited Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
EP2138167A1 (en) * 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
DE102008031038A1 (de) 2008-06-30 2009-12-31 Alexander Priv.-Doz. Dr. Dömling Sutent zur Anwendung in der Organtransplantation
EP2307421A4 (en) * 2008-06-30 2011-07-13 Cylene Pharmaceuticals Inc OXINDOLE COMPOUNDS
SG10201510586PA (en) 2008-06-30 2016-01-28 Mesoblast Inc Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy
WO2010001167A2 (en) * 2008-07-02 2010-01-07 Generics [Uk] Limited Novel process
JP2011527330A (ja) * 2008-07-10 2011-10-27 ジェネリクス・（ユーケー）・リミテッド スニチニブリンゴ酸塩の結晶形の調製方法
KR20110036588A (ko) 2008-07-24 2011-04-07 테바 파마슈티컬 인더스트리즈 리미티드 수니티닙 아세테이트 및 이의 다형을 통한 수니티닙 말레이트의 제조 방법
WO2010010454A2 (en) 2008-07-24 2010-01-28 Medichem, S.A. Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
US8993615B2 (en) 2008-08-08 2015-03-31 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
CN102197035A (zh) * 2008-08-25 2011-09-21 基因里克斯(英国)有限公司 舒尼替尼的结晶形式及其制备方法
JP2012500652A (ja) * 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド 標的化共刺激ポリペプチドおよび癌を処置するための使用方法
CN102197034A (zh) * 2008-08-25 2011-09-21 基因里克斯(英国)有限公司 舒尼替尼的新型多晶型物及其制备方法
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
KR20110066927A (ko) * 2008-09-05 2011-06-17 임페리얼 이노베이션스 리미티드 생체 내 영상화제로서 사용하기 위한 이사틴 유도체
US8192738B2 (en) 2008-09-19 2012-06-05 Medimmune, Llc Targeted antibodies directed to DLL4
CN102177155A (zh) * 2008-10-10 2011-09-07 麦迪凯姆股份公司 一种3-吡咯取代的2-吲哚酮苹果酸盐的制备工艺
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
US20100222371A1 (en) * 2008-11-20 2010-09-02 Children's Medical Center Corporation Prevention of surgical adhesions
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
UY32351A (es) 2008-12-22 2010-07-30 Astrazeneca Ab Compuestos de pirimidinil indol para uso como inhibidores de atr
CA2748158A1 (en) 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
EP2373643A4 (en) 2009-01-02 2013-08-07 Hetero Research Foundation NEW SUNITINIB MALATE POLYMORPHS
AU2010204619B2 (en) 2009-01-16 2016-08-11 Exelixis, Inc. Malate salt of N-(4-{ [ 6, 7-bis (methyloxy)-quinolin-4-yl] oxy}phenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
NZ620649A (en) 2009-02-05 2015-09-25 Immunogen Inc Novel benzodiazepine derivatives
WO2010090764A1 (en) 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
WO2010098888A1 (en) * 2009-02-27 2010-09-02 Massachusetts Institute Of Technology Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
EP2406258B1 (en) 2009-03-13 2014-12-03 Cellzome Limited PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
US20120040955A1 (en) 2009-04-14 2012-02-16 Richard John Harrison Fluoro substituted pyrimidine compounds as jak3 inhibitors
US8530492B2 (en) 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
EP2264027A1 (en) * 2009-05-27 2010-12-22 Ratiopharm GmbH Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2771675A1 (en) 2009-09-11 2011-03-17 Cellzome Limited Ortho substituted pyrimidine compounds as jak inhibitors
CA2774634A1 (en) 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Salts of sunitinib
KR20120102601A (ko) 2009-10-20 2012-09-18 셀좀 리미티드 Ｊａｋ 저해제로서의 헤테로시클릴 피라졸로피리미딘 유사체
WO2011058521A2 (en) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
WO2011061613A1 (en) 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Process for the preparation of crystalline form ii of l-malic acid salt of sunitinib
RU2706200C2 (ru) 2009-11-24 2019-11-14 Медиммьюн Лимитед Специфические связывающие агенты против в7-н1
EP2507237A1 (en) 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2011095802A1 (en) 2010-02-02 2011-08-11 Generics [Uk] Limited Hplc method for analyzing sunitinib
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
EP2539337A1 (en) 2010-02-22 2013-01-02 F. Hoffmann-La Roche AG Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
WO2011104555A2 (en) * 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
WO2011107585A1 (en) 2010-03-04 2011-09-09 Cellzome Limited Morpholino substituted urea derivatives as mtor inhibitors
CA2792039A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
WO2011110199A1 (en) 2010-03-10 2011-09-15 Synthon B.V. A process for amidation of pyrrole carboxylate compounds
WO2011114246A1 (en) 2010-03-18 2011-09-22 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
WO2011119777A2 (en) 2010-03-23 2011-09-29 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
SG184989A1 (en) 2010-04-30 2012-11-29 Cellzome Ltd Pyrazole compounds as jak inhibitors
WO2011138565A1 (fr) 2010-05-05 2011-11-10 Biorebus Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
EP2392324A1 (en) 2010-06-01 2011-12-07 Societe De Coordination De Recherches Therapeutiques Rhenium complexes and their pharmaceutical use
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
RU2560683C2 (ru) 2010-06-25 2015-08-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
US20130143915A1 (en) 2010-07-01 2013-06-06 Cellzome Limited Triazolopyridines as tyk2 inhibitors
KR20130120439A (ko) 2010-07-09 2013-11-04 제넨테크, 인크. 항-뉴로필린 항체 및 사용 방법
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
US9040545B2 (en) 2010-08-20 2015-05-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
US8426418B2 (en) 2010-08-27 2013-04-23 CollabRx Inc. Method to treat melanoma in BRAF inhibitor-resistant subjects
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
WO2012058780A1 (en) 2010-11-01 2012-05-10 Scinopharm (Kunshan) Biochemical Technology Co., Ltd. Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
WO2012059941A1 (en) * 2010-11-04 2012-05-10 Ind-Swift Laboratories Limited Process for preparation of sunitinib malate and salts thereof
CA2815330A1 (en) 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
JP2014503500A (ja) 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
AR083868A1 (es) 2010-12-03 2013-03-27 Lilly Co Eli Compuestos de oxazol[5,4-b]piridin-5-ilo
WO2012088529A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-sunitinib conjugates
WO2012088522A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
EP2670753B1 (en) 2011-01-31 2016-10-19 Novartis AG Novel heterocyclic derivatives
SG191955A1 (en) 2011-02-15 2013-08-30 Immunogen Inc Cytotoxic benzodiazepine derivatives
CA2827171C (en) 2011-02-17 2019-04-09 Cancer Therapeutics Crc Pty Limited Fak inhibitors
CN103534240B (zh) 2011-02-17 2015-12-09 癌症疗法Crc私人有限公司 选择性fak抑制剂
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
US8630703B2 (en) 2011-03-09 2014-01-14 Technion Research & Development Foundation Limited Treatment utilizing hydrophobic weak bases chemotherapeutic agents and illumination
CN102115469A (zh) * 2011-03-21 2011-07-06 浙江大学 吲哚啉-2-酮类衍生物的制备和用途
WO2012136622A1 (en) 2011-04-04 2012-10-11 Cellzome Limited Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
BR112013025679A2 (pt) * 2011-04-08 2016-07-19 Beta Pharma Inc inibidores de proteína quinase de novos compostos de indolinona
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
CN102898402B (zh) * 2011-04-26 2016-01-20 北京大学 一种苯并异硒唑酮修饰的吡咯甲酸酯取代的吲哚酮类化合物及其应用
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
HUE052198T2 (hu) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology Inc Heterociklusos protein kináz inhibitorok
BR112014000360A2 (pt) 2011-07-28 2017-02-14 Cellzome Ltd análogos de heterociclil pirimidina como inibidores jak
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
US20140323504A1 (en) 2011-09-20 2014-10-30 Cellzome Limited Pyrazolo[4,3-c]Pyridine Derivatives As Kinase Inhibitors
AU2012311458B2 (en) 2011-09-21 2016-02-04 Cellzome Limited Morpholino substituted urea or carbamate derivatives as mTOR inhibitors
MX341577B (es) 2011-10-07 2016-08-25 Cellzome Ltd Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero.
CN102499917B (zh) 2011-10-25 2014-12-17 澳门大学 吲哚酮类化合物在制备神经保护药物中的应用
EA023935B1 (ru) 2011-10-28 2016-07-29 Новартис Аг Производные пурина и их применение для лечения заболевания
CN103130774B (zh) * 2011-11-22 2016-06-22 齐鲁制药有限公司 具有酪氨酸激酶抑制作用的化合物及其制备方法和应用
CN103127096B (zh) * 2011-12-02 2015-11-25 杨子娇 吡咯基取代的吲哚类化合物在治疗青光眼病的应用
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
JP2015500862A (ja) 2011-12-23 2015-01-08 セルゾーム リミティッド キナーゼ阻害剤としてのピリミジン−２，４−ジアミン誘導体
CN102491932A (zh) * 2011-12-26 2012-06-13 天津科技大学 一种3-吲哚啉酮类衍生物及其制备方法及其应用
ES2709110T3 (es) 2012-03-23 2019-04-15 Laurus Labs Ltd Un proceso mejorado para la preparación de sunitinib y sus sales de adición de ácido
ES2621257T3 (es) 2012-04-20 2017-07-03 Annji Pharmaceutical Co., Ltd. Ésteres de ciclopropanocarboxilato de análogos de purinas
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
CN102653521B (zh) * 2012-04-27 2014-08-06 首都师范大学 吲哚-2-酮的哌嗪硫代甲酰肼衍生物及其制备方法和用途
SG10201603896RA (en) 2012-05-04 2016-07-28 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
SG11201406550QA (en) 2012-05-16 2014-11-27 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
HUE043552T2 (hu) 2012-06-08 2019-09-30 Sutro Biopharma Inc Antitestek, amelyek tartalmaznak helyspecifikus nem természetes aminosav maradékokat, eljárások elõállításukra és eljárások használatukra
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
EP2885291A4 (en) 2012-08-17 2015-11-04 Cancer Therapeutics Crc Pty Ltd INHIBITORS OF VEGFR3
WO2014031566A1 (en) 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
HRP20220455T1 (hr) 2012-08-31 2022-05-27 Sutro Biopharma, Inc. Modificirane aminokiseline koje sadrže azid grupu
WO2014041349A1 (en) 2012-09-12 2014-03-20 Cancer Therapeutics Crc Pty Ltd Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
JP6243918B2 (ja) 2012-10-16 2017-12-06 トレロ ファーマシューティカルズ， インコーポレイテッド Ｐｋｍ２調節因子およびそれらの使用方法
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
JP6423804B2 (ja) 2013-02-28 2018-11-14 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤を含む複合体
WO2014134483A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
RU2019104092A (ru) * 2013-03-13 2019-03-20 Бостон Байомедикал, Инк. Производные 3-(арил или гетероарил)метилениндолин-2-она в качестве ингибиторов киназного пути раковых стволовых клеток для лечения рака
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
TR201911151T4 (tr) 2013-03-14 2019-08-21 Tolero Pharmaceuticals Inc Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri.
AR095443A1 (es) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
CN104119321B (zh) * 2013-04-28 2017-09-08 齐鲁制药有限公司 二氢吲哚酮衍生物的二马来酸盐及其多晶型物
MX368099B (es) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
JP6612232B2 (ja) 2013-08-28 2019-11-27 クラウン バイオサイエンス インコーポレイテッド（タイカン） 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US9604968B2 (en) 2013-10-18 2017-03-28 Sun Pharmaceutical Industries Limited Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
CA2838585A1 (en) 2013-10-18 2015-04-18 Hari Babu Matta An ascorbic acid salt of sunitinib
KR102196884B1 (ko) 2013-11-01 2020-12-30 화이자 인코포레이티드 전립선-연관 항원의 발현을 위한 벡터
SI3076969T1 (sl) 2013-12-06 2021-12-31 Novartis Ag Režim omderjanja izooblike alfa selektivnega zaviralca fosfatidilino- zitol 3-kinaze
CN104829596B (zh) * 2014-02-10 2017-02-01 石家庄以岭药业股份有限公司 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
CN103923014A (zh) * 2014-05-05 2014-07-16 宁夏宝马药业有限公司 环肌酸制备方法
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
JP6659554B2 (ja) 2014-08-28 2020-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 高純度キノリン誘導体およびその製造方法
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
JP6852848B2 (ja) 2015-01-13 2021-03-31 国立大学法人京都大学 筋萎縮性側索硬化症の予防及び／又は治療剤
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX2017013383A (es) 2015-04-20 2017-12-07 Tolero Pharmaceuticals Inc Prediccion de respuesta a alvocidib mediante perfilado mitocondrial.
WO2016184793A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
MX380798B (es) 2015-05-18 2025-03-12 Sumitomo Pharma Oncology Inc Profármacos de alvocidib que tienen una biodisponibilidad aumentada.
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP7083497B2 (ja) 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー， インコーポレイテッド がんの処置のための併用療法
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
HK1256721A1 (zh) 2015-09-22 2019-10-04 灰色视觉公司 用於治疗眼部病症的化合物和组合物
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
US20180280370A1 (en) 2015-11-02 2018-10-04 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
SG11201803663XA (en) 2015-11-12 2018-05-30 Graybug Vision Inc Aggregating microparticles for therapy
RU2018130757A (ru) 2016-01-27 2020-02-27 Сутро Биофарма, Инк. Конъюгаты антитела к cd74, композиции, содержащие конъюгаты антитела к cd74, и способы использования конъюгатов антитела к cd74
EP3414330A4 (en) 2016-02-08 2019-07-03 Vitrisa Therapeutics, Inc. COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF TIME AND USES THEREOF
EP3228630A1 (en) 2016-04-07 2017-10-11 IMBA-Institut für Molekulare Biotechnologie GmbH Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
CN107459519A (zh) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
US10870694B2 (en) 2016-09-02 2020-12-22 Dana Farber Cancer Institute, Inc. Composition and methods of treating B cell disorders
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
KR20190084063A (ko) 2016-10-28 2019-07-15 이칸 스쿨 오브 메디슨 엣 마운트 시나이 Ｅｚｈ２-매개성 암 치료용 조성물 및 방법
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018106606A1 (en) 2016-12-05 2018-06-14 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
JP2020514252A (ja) 2016-12-08 2020-05-21 アイカーン スクール オブ メディスン アット マウント シナイ Ｃｄｋ４／６媒介性がんを治療するための組成物および方法
EP3362471B1 (en) 2016-12-19 2021-11-17 Sumitomo Dainippon Pharma Oncology, Inc. Profiling peptides and methods for sensitivity profiling
KR102539920B1 (ko) 2017-02-08 2023-06-05 에자이 알앤드디 매니지먼트 가부시키가이샤 종양-치료용 약제학적 조성물
CN106916143B (zh) * 2017-03-14 2019-09-27 哈尔滨医科大学 一种预防和治疗冠心病的药物及其应用
RU2019133337A (ru) 2017-03-23 2021-04-23 Грейбуг Вижн, Инк. Лекарственные средства и композиции для лечения глазных нарушений
EP3621654A4 (en) 2017-05-10 2021-02-17 Graybug Vision, Inc. PROLONGED-RELEASE MICROPARTICLES AND SUSPENSIONS OF THESE INTENDED FOR MEDICAL THERAPY
US20200197384A1 (en) 2017-05-16 2020-06-25 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
EP3658588A1 (en) 2017-07-26 2020-06-03 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
BR112020005212A2 (pt) 2017-09-18 2020-09-15 Sutro Biopharma, Inc. conjugado de anticorpo, kit, composição farmacêutica, e, métodos de tratamento ou prevenção e de diagnóstico de uma doença ou condição.
WO2019075367A1 (en) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
NL2019801B1 (en) 2017-10-25 2019-05-02 Univ Leiden Delivery vectors
AU2019231689A1 (en) 2018-03-06 2020-09-24 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
EP3802519A1 (en) 2018-06-04 2021-04-14 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
CN112996518A (zh) 2018-06-21 2021-06-18 西奈山伊坎医学院 Wd40重复结构域蛋白5(wdr5)降解/破坏化合物和使用方法
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
JP2021530554A (ja) 2018-07-26 2021-11-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 異常なａｃｖｒ１発現を伴う疾患を処置するための方法およびそこで使用するためのａｃｖｒ１阻害剤
EP3852811A1 (en) 2018-09-17 2021-07-28 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
CA3119807A1 (en) 2018-12-04 2020-06-11 Sumitomo Dainippon Pharma Oncology, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
US11471456B2 (en) 2019-02-12 2022-10-18 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
CN113747895A (zh) 2019-03-22 2021-12-03 大日本住友制药肿瘤公司 包含pkm2调节剂的组合物和用其治疗的方法
CN113646303A (zh) 2019-03-28 2021-11-12 安普利亚治疗有限公司 Fak抑制剂的盐和晶型
EP3958845A1 (en) 2019-04-25 2022-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
WO2020227105A1 (en) 2019-05-03 2020-11-12 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
EP4524137A3 (en) * 2019-05-06 2025-04-30 Icahn School of Medicine at Mount Sinai Heterobifunctional compounds as degraders of hpk1
US20220298143A1 (en) 2019-08-31 2022-09-22 Etern Biopharma (Shanghai) Co., Ltd. Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4114852A1 (en) 2020-03-03 2023-01-11 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
CN111233841A (zh) * 2020-03-17 2020-06-05 湖北扬信医药科技有限公司 一种舒尼替尼有关物质及其制备方法和用途
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
JP7633786B2 (ja) * 2020-09-18 2025-02-20 日本化薬株式会社 スニチニブリンゴ酸塩を有効成分とする医薬錠剤
US20240293365A1 (en) * 2021-06-28 2024-09-05 The Regents Of The University Of California Methods for treating and ameliorating t cell related diseases
CN113717159A (zh) * 2021-09-16 2021-11-30 中国药科大学 吲哚酮类化合物及其药物组合物、制备方法及用途
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
KR20250012631A (ko) 2022-05-24 2025-01-24 다이이찌 산쿄 가부시키가이샤 항-cdh6 항체-약물 접합체의 투약
CN120076831A (zh) 2022-06-30 2025-05-30 苏特罗生物制药公司 抗ror1抗体和抗体缀合物、包含抗ror1抗体或抗体缀合物的组合物、以及制备和使用抗ror1抗体和抗体缀合物的方法
CN119233974A (zh) * 2022-07-22 2024-12-31 康百达（四川）生物医药科技有限公司 一种吲哚酮衍生物及其应用
CN118221652B (zh) * 2022-12-19 2025-06-06 沈阳药科大学 一种吲哚-2-酮衍生物及其制备方法和用途
WO2024188282A1 (zh) * 2023-03-14 2024-09-19 康百达（四川）生物医药科技有限公司 吲哚酮衍生物及其在医药上的应用
WO2025081117A2 (en) 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
WO2025250825A1 (en) 2024-05-30 2025-12-04 Sutro Biopharma, Inc. Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL230368A (enExample) 1957-08-19
DE878539C (de) 1939-08-17 1953-06-05 Hoechst Ag Verfahren zur Herstellung von Methinfarbstoffen
BE507136A (enExample) 1950-11-18
BE553661A (enExample) 1955-12-23
BE558210A (enExample) 1956-06-08
NL251055A (enExample) 1959-04-29
FR1398224A (fr) 1964-05-06 1965-05-07 Ici Ltd Procédé de teinture de matières textiles de polyacrylonitrile
US3308134A (en) 1965-10-22 1967-03-07 Mcneilab Inc Spiro(indan-2, 3'-indoline)-1, 2'-diones
US3551571A (en) 1967-05-19 1970-12-29 Endo Lab Methods for reducing pain,reducing fever and alleviating inflammatory syndromes with heteroaromatic pyrrol-3-yl ketones
US3564016A (en) 1968-03-07 1971-02-16 Endo Lab Method of decarbonylation
US4070366A (en) 1968-06-12 1978-01-24 Canadian Patents & Development Limited Alkylation process
FR1599772A (enExample) 1968-09-17 1970-07-20
US3922163A (en) 1970-01-30 1975-11-25 Upjohn Co Organic compounds and process
US3715364A (en) 1970-12-28 1973-02-06 Merck & Co Inc Nitroimidazole carboxamides
DE2159361A1 (de) 1971-11-30 1973-06-14 Bayer Ag Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2159362A1 (de) 1971-11-30 1973-06-14 Bayer Ag Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2159360A1 (de) 1971-11-30 1973-06-14 Bayer Ag Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2159363A1 (de) 1971-11-30 1973-06-14 Bayer Ag Antimikrobielle mittel
GB1384599A (en) 1972-05-04 1975-02-19 Colgate Palmolive Co Coloured detergent compositions
US3880871A (en) 1973-09-27 1975-04-29 Squibb & Sons Inc Isothiocyanophenyl substituted imidazoles
US4002643A (en) 1975-06-27 1977-01-11 Mcneil Laboratories, Inc. Preparation of β-acyl pyrroles
US4002749A (en) 1975-08-12 1977-01-11 E. R. Squibb & Sons, Inc. Substituted indolinones
US4053613A (en) 1975-09-17 1977-10-11 E. R. Squibb & Sons, Inc. 1,3,thiazolinyl and 1,3 thiazinyl substituted indolinones
DE2855306A1 (de) 1978-12-21 1980-07-10 Boehringer Sohn Ingelheim Mittel zur senkung der herzfrequenz
GR73560B (enExample) 1979-02-24 1984-03-15 Pfizer
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4343923A (en) 1980-08-07 1982-08-10 Armstrong World Industries, Inc. Process for reducing the acid dye uptake of polyamide textile materials with N-acylimidazole compound
CH646956A5 (de) 1981-12-15 1984-12-28 Ciba Geigy Ag Imidazolide.
EP0095285A1 (en) 1982-05-21 1983-11-30 Sumitomo Chemical Company, Limited N-acylimidazoles, their production and use
US4493642A (en) 1982-12-27 1985-01-15 Bogdon Glendon J Orthodontic device and associated orthodontic method
DE3310891A1 (de) 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US4489089A (en) 1983-04-06 1984-12-18 American Cyanamid Company Substituted N-[ω-(1H-imidazol-1-yl)alkyl]-amides
DE3480392D1 (en) 1983-04-29 1989-12-14 Ciba Geigy Ag Imidazolides and their use as curing agents for polyepoxides
DE3415138A1 (de) 1984-04-21 1985-10-31 Basf Ag, 6700 Ludwigshafen N-(azolylcarbamoyl)-hydroxylamine und diese enthaltende fungizide
DE3426419A1 (de) 1984-07-18 1986-01-23 Boehringer Mannheim Gmbh, 6800 Mannheim Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US4560700A (en) 1985-02-08 1985-12-24 Merrell Dow Pharmaceuticals Inc. Pyrrole-3-carboxylate cardiotonic agents
JPH078851B2 (ja) 1985-07-29 1995-02-01 鐘淵化学工業株式会社 ３−フエニルチオメチルスチレン誘導体
JPS6229570A (ja) 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd ３，５−ジイソプロピルベンジリデン複素環式化合物
JPS6239564A (ja) 1985-08-13 1987-02-20 Kanegafuchi Chem Ind Co Ltd α−ベンジリデン−γ−ブチロラクトンまたはγ−ブチロラクタム誘導体
US4966849A (en) 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
WO1993012786A1 (en) 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
US4853404A (en) 1986-10-13 1989-08-01 Tanabe Seiyaku Co., Ltd. Phenoxyacetic acid derivatives composition and use
JPS63141955A (ja) 1986-12-03 1988-06-14 Kanegafuchi Chem Ind Co Ltd トリベンジルアミン誘導体
US5089516A (en) 1987-03-11 1992-02-18 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity
US5202341A (en) 1987-03-11 1993-04-13 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds having tyrosine kinase inhibiting activity
WO1988007035A1 (fr) 1987-03-11 1988-09-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Derives d'hydroxystyrene
US5043348A (en) 1987-04-24 1991-08-27 Cassella Aktiengesellschaft Pyrrolealdehydes, their preparation and their use
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3808071A1 (de) 1988-03-11 1989-09-21 Basf Ag Verfahren zur herstellung von acylierten imidazolen
US4868304A (en) 1988-05-27 1989-09-19 Iowa State University Research Foundation, Inc. Synthesis of nitrogen heterocycles
CA1339784C (en) 1988-06-23 1998-03-31 Shinya Inoue Pyrrolecarboxylic acid derivatives
JPH06104658B2 (ja) 1988-06-23 1994-12-21 三菱化成株式会社 ピロールカルボン酸誘導体
DE3824658A1 (de) 1988-07-15 1990-01-18 Schering Ag N-hetaryl-imidazolderivate
GB8816944D0 (en) 1988-07-15 1988-08-17 Sobio Lab Compounds
US5084280A (en) 1988-12-15 1992-01-28 Chapman Chemical Company Wood preservation composition and method
DE3902439A1 (de) 1989-01-27 1990-08-02 Basf Ag Pflanzenschuetzende mittel auf basis von 1-aryl- bzw. 1-hetarylimidazolcarbonsaeureestern
US5047554A (en) 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
DK0429685T3 (da) 1989-07-25 1997-12-15 Taiho Pharmaceutical Co Ltd Oxoindolderivat
US5258357A (en) 1989-10-07 1993-11-02 Basf Aktiengesellschaft Carboxamides, their preparation and their use as herbicides
CA2032421A1 (en) 1989-12-20 1991-06-21 Mitsubishi Chemical Corporation Pyrrolealdehyde derivative
GB9004483D0 (en) 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
CA2012634A1 (en) 1990-03-20 1991-09-20 Hassan Salari Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases
FI924427L (fi) 1990-04-02 1992-10-01 Pfizer Bensylfosfonsyratyrosinkinas-inhibitorer
US5196446A (en) 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
JP2944721B2 (ja) 1990-08-22 1999-09-06 生化学工業株式会社 エンドトキシンの測定剤
WO1992007830A2 (en) 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
IT1247509B (it) 1991-04-19 1994-12-17 Univ Cagliari Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ATE159009T1 (de) 1991-05-10 1997-10-15 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US6194439B1 (en) 1991-05-29 2001-02-27 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
GB9115160D0 (en) 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
US5124347A (en) 1991-07-31 1992-06-23 Warner-Lambert Co. 3-5-ditertiarybutylphenyl-4-hydroxymethylidene derivatives of 1,3-dihydro-2H-indole-2-ones as antiinflammatory agents
JPH0558894A (ja) 1991-08-27 1993-03-09 Kanegafuchi Chem Ind Co Ltd 抗腫瘍剤
SK44894A3 (en) 1991-10-18 1995-04-12 Monsanto Co Trisubstituted aromatic compounds, method of their preparation and fungicidal agents
US5389661A (en) 1991-12-05 1995-02-14 Warner-Lambert Company Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties
US5322950A (en) 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
FR2689397A1 (fr) 1992-04-01 1993-10-08 Adir Utilisation des dérivés de la 3-(3,5-Ditert-Butyl-4-Hydroxybenzylidenyl) Indoline-2-one pour l'obtention de médicaments.
DE4211531A1 (de) 1992-04-06 1993-10-07 Cassella Ag Verfahren zur Herstellung von Pyrrolderivaten
EP0641204B1 (en) 1992-05-20 2000-08-16 Merck & Co. Inc. 17-ethers and thioethers of 4-aza-steroids
FR2694004B1 (fr) 1992-07-21 1994-08-26 Adir Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
RU2155187C2 (ru) 1992-08-06 2000-08-27 Варнер-Ламберт Компани Производные индола, их таутомеры, смеси их изомеров или отдельные изомеры и фармацевтически приемлемые соли, фармацевтическая композиция с антиопухолевой или ингибирующей протеин-тирозинкиназу активностью и способ торможения зависящего от протеин-тирозинкиназы заболевания или борьбы с аберрантным ростом клеток млекопитающего или человека.
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
CA2145985C (en) 1992-10-28 2003-09-16 Napoleone Ferrara Vascular endothelial cell growth factor antagonists
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
JP3507124B2 (ja) 1993-05-26 2004-03-15 塩野義製薬株式会社 ベンジリデン誘導体の製造法
DE59402281D1 (de) 1993-06-28 1997-05-07 Bayer Ag Massefärben von Kunststoffen
GB9313638D0 (en) 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
US5332736A (en) 1993-11-01 1994-07-26 Ortho Pharmaceutical Corporation Anti-convulsant aroyl aminoacylpyrroles
US5502072A (en) 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
GB9326136D0 (en) 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
US5610173A (en) 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9423997D0 (en) 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5786488A (en) 1996-11-13 1998-07-28 Sugen, Inc. Synthetic methods for the preparation of indolyquinones
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JP3246712B2 (ja) 1995-11-15 2002-01-15 株式会社トクヤマ エテニルアミド化合物の製造方法
AU708167B2 (en) 1996-01-17 1999-07-29 Taiho Pharmaceutical Co., Ltd. Intimal hypertrophy inhibitors
EP0788890A1 (en) 1996-02-06 1997-08-13 Agfa-Gevaert N.V. Dyes and dye-donor elements for thermal dye transfer recording
AU2066797A (en) 1996-03-21 1997-10-10 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
EP0894085B1 (en) 1996-03-29 2005-08-17 Pfizer Inc. Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-ht1a- and/or 5-ht1d receptors
CA2206201A1 (en) 1996-05-29 1997-11-29 Yoshiaki Isobe Pyrazole derivatives and their pharmaceutical use
DE59711058D1 (de) 1996-08-01 2004-01-08 Merckle Gmbh Acylpyrroldicarbonsäuren und acylindoldicarbonsäuren sowie ihre derivate als hemmstoffe der cytosolischen phospholipase a2
JP2001514484A (ja) 1996-08-21 2001-09-11 スージェン・インコーポレーテッド タンパク質チロシンキナーゼの結晶構造
ES2251741T3 (es) 1996-08-23 2006-05-01 Sugen, Inc. Bibliotecas combinatorias de indolinona y productos afines y metodos para el tratamiento de enfermedades.
WO1998024432A2 (en) 1996-12-05 1998-06-11 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
CA2282439C (en) 1997-03-05 2010-05-04 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
WO1998045708A1 (en) 1997-04-08 1998-10-15 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
EP0984930B1 (en) * 1997-05-07 2005-04-06 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
EP1007042A4 (en) 1997-06-13 2001-07-04 Sugen Inc NEW HETEROCYCLIC COMPOUNDS FOR MODULATING THE PROTEIN-TYROSIN-ENZYME-RELATED CELLULAR SIGNAL TRANSDUCTION
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
UA58476C2 (uk) 1997-10-09 2003-08-15 Санофі-Сентелябо Похідні 8-азабіцикло[3.2.1]октан-3-метанаміну, фармацевтична композиція та лікарський засіб
WO2000008202A2 (en) 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
CA2325935A1 (en) 1998-03-26 1999-09-30 Sugen, Inc. Heterocyclic families of compounds for the modulation of tyrosine protein kinase
DE19816624A1 (de) 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
CO5031249A1 (es) 1998-05-29 2001-04-27 Sugen Inc Pirrol substituido-2-indolinonas inhibidoras de proteinci-nasas
DE19826940A1 (de) 1998-06-17 1999-12-23 Bayer Ag Substituierte N-Aryl-O-alkyl-carbamate
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
PL348817A1 (en) 1998-12-14 2002-06-17 Cellegy Pharmaceuticals Compositions and methods for the treatment of anorectal disorders
TR200101860T2 (tr) * 1998-12-17 2001-12-21 F.Hoffmann-La Roche Ag Sikline bağlı kinaz inhibitörleri olarak 4-alkenil (ve alkinil) oksidoller
US6284894B1 (en) 1998-12-18 2001-09-04 Nycomed Imaging As Preparation of allylic aromatic compounds
IL143920A0 (en) * 1998-12-31 2002-04-21 Sugen Inc 3-heteroarylidenyl-2-indolinone derivatives and pharmaceutical compositions containing the same
WO2000056709A1 (en) 1999-03-24 2000-09-28 Sugen, Inc. Indolinone compounds as kinase inhibitors
JP5336686B2 (ja) * 1999-11-24 2013-11-06 スージェン， インク． 遊離酸または遊離塩基としてイオン化可能な医薬品のための処方
CA2395461C (en) * 1999-12-22 2010-05-25 Sugen, Inc. Methods of modulating c-kit tyrosine kinase function with indolinone compounds
EP1255752B1 (en) * 2000-02-15 2007-08-08 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
TWI270545B (en) 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
EP1296975A1 (en) * 2000-06-30 2003-04-02 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
AR035721A1 (es) * 2000-12-20 2004-07-07 Sugen Inc Indolinonas 4-aril sustituidas; sus composiciones farmaceuticas y metodo para modular la actividad catalitica de una proteina quinasa

Also Published As

Publication number Publication date
NL300430I2 (nl) 2010-04-01
CN1439005A (zh) 2003-08-27
CN1329390C (zh) 2007-08-01
FR10C0003I1 (fr) 2010-03-05
ATE369359T1 (de) 2007-08-15
HRP20020751B1 (hr) 2011-01-31
US20040063773A1 (en) 2004-04-01
FR08C0002I2 (fr) 2009-01-02
PL211834B1 (pl) 2012-06-29
HU228979B1 (en) 2013-07-29
ES2290117T3 (es) 2008-02-16
US7572924B2 (en) 2009-08-11
TWI306860B (en) 2009-03-01
EP1255752A2 (en) 2002-11-13
CO5280092A1 (es) 2003-05-30
US6573293B2 (en) 2003-06-03
SI1255752T1 (sl) 2007-12-31
BRPI0117360A2 (pt) 2012-01-24
WO2001060814A3 (en) 2002-01-24
AU2001239770B2 (en) 2006-01-05
ME00415B (me) 2011-10-10
CA2399358A1 (en) 2001-08-23
UA73976C2 (uk) 2005-10-17
DK1255752T3 (da) 2007-11-26
EA005996B1 (ru) 2005-08-25
NL300332I1 (nl) 2008-03-03
NO20023831D0 (no) 2002-08-13
SK13262002A3 (sk) 2003-03-04
BRPI0117360B8 (pt) 2021-07-06
US7125905B2 (en) 2006-10-24
FR08C0002I1 (enExample) 2008-03-21
HUP0204433A3 (en) 2007-08-28
KR20030003229A (ko) 2003-01-09
NO2019005I1 (no) 2019-02-11
CR20120009A (es) 2012-02-07
US20070010569A1 (en) 2007-01-11
DE122010000004I1 (de) 2010-04-15
FR10C0003I2 (fr) 2012-06-22
JP2003523340A (ja) 2003-08-05
NZ520640A (en) 2005-04-29
BRPI0117360B1 (pt) 2018-11-13
DE122008000002I1 (de) 2008-04-17
IL151127A0 (en) 2003-04-10
LTC1255752I2 (lt) 2019-08-26
BG65764B1 (bg) 2009-10-30
CY2010004I2 (el) 2012-01-25
CY2010004I1 (el) 2012-01-25
RS50444B (sr) 2010-03-02
BE2010C009I2 (enExample) 2020-01-30
CY1108032T1 (el) 2011-04-06
CR20120007A (es) 2012-02-24
CA2399358C (en) 2006-03-21
EA200200862A1 (ru) 2003-02-27
MY130363A (en) 2007-06-29
NO2010002I2 (no) 2010-12-06
LU91407I9 (enExample) 2018-12-28
NL300332I2 (nl) 2008-04-01
NL300430I1 (nl) 2010-03-01
LU91407I2 (fr) 2008-03-10
HUP0204433A2 (hu) 2003-04-28
PL361209A1 (en) 2004-09-20
WO2001060814A2 (en) 2001-08-23
DE60129794D1 (de) 2007-09-20
BR0108394A (pt) 2004-06-22
HRP20020751A2 (en) 2004-12-31
NO2008019I2 (no) 2011-10-17
NO20023831L (no) 2002-10-15
US20020156292A1 (en) 2002-10-24
CY2008004I2 (el) 2009-11-04
IS2491B (is) 2009-01-15
AR034118A1 (es) 2004-02-04
YU61402A (sh) 2005-07-19
HK1051188A1 (en) 2003-07-25
DE60129794T2 (de) 2007-12-06
KR100713960B1 (ko) 2007-05-02
NO2010002I1 (no) 2010-03-08
PE20011083A1 (es) 2001-10-26
BG107078A (bg) 2003-04-30
SK287142B6 (sk) 2010-01-07
CZ303705B6 (cs) 2013-03-27
AU3977001A (en) 2001-08-27
CY2008004I1 (el) 2009-11-04
LTPA2008002I1 (lt) 2019-02-25
NO2008019I1 (no) 2009-01-12
LU91657I2 (fr) 2010-05-03
MXPA02008021A (es) 2004-04-05
NO325532B1 (no) 2008-06-09
BRPI0108394B1 (pt) 2018-12-11
EP1255752B1 (en) 2007-08-08
PT1255752E (pt) 2007-10-17
IS6501A (is) 2002-08-13
US20050176802A1 (en) 2005-08-11
CZ20023081A3 (cs) 2003-02-12
JP3663382B2 (ja) 2005-06-22

Similar Documents

Publication Publication Date Title
BRPI0108394B8 (pt) inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
BR0207494A (pt) Derivados de 3-(4-amidopirrol-2-ilmetilideno)-2-indolinona como inibidores de proteìna quinase
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BRPI0416692A (pt) inibidores heterocìclicos de mek e métodos de emprego destes
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
BRPI0411868B8 (pt) derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
MXPA02005844A (es) Inhibidores de cinasas de proteina.
BR0315912A (pt) Compostos pirimìdicos com atividade antiproliferativa (ii)
NO20040547L (no) Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse.
BRPI0411863A (pt) derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
BR0312232A (pt) Inibidores de caspases e seus usos
BR9909688A (pt) Indolinonas substituìdas, a sua preparação e seu uso como composições farmacêuticas
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
BR0213037A (pt) Derivados de pirimidina
BR0009561A (pt) 1,4-didro indeno [1,2-c] pirazóis substituìdos como inbidores de tirosina cinase
GT200500020A (es) Derivados de 1h-tieno[2,3-c]pirazol utiles como inhibidores de quinasa.
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
BR0112655A (pt) Derivados de pirrolidino como inibidores de metaloproteases
BR0113752A (pt) Derivados piperidina para uso inibidores 2,3-óxido esqualeno lanoesterol ciclase
TW200508236A (en) Pyrazolo[1,5-a]pyrimidine derivatives

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/12/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/02/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 15/02/2021

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.012897/2021-28 ORIGEM: 14A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1087133-48.2021.4.01.3400 ACAO DE PROCEDIMENTO COMUM COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: PHARMACIA AND UPJOHN COMPANY E SUGEN, INC REU(S): INPI - INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL

B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.001366/2022-91 NUP: 00424.035864/2022-85 (REF. 1003240-43.2022.4.01.0000) INTERESSADOS: PHARMACIA AND UPJOHN COMPANY E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI. 2 SENTENCA: DEFIRO O PEDIDO DE ANTECIPACAO DA TUTELA RECURSAL FORMULADO NA INICIAL, PARA RESTABELECER A VIGENCIA DA PATENTE PI0108394-5, ATE A REALIZACAO DA PROVA PERICIAL, VISANDO A APURAR A DEMORA SUPOSTAMENTE INJUSTIFICADA DO INPI DURANTE O RESPECTIVO PROCESSO DE CONCESSAO.

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 CONFORME DETERMINADO NO PROCESSO INPI NO 52402.001366/2022-91 NUP: 00424.035864/2022-85 (REF. 1003240-43.2022.4.01.0000) QUANTO AO PRAZO DE VALIDADE.

B21I Extinguishment of a patent or of a certificate of addition of invention: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 21.1 NA RPI NO 2630 DE 01/06/2021 CONFORME DETERMINADO NO PROCESSO INPI NO 52402.001366/2022-91 NUP: 00424.035864/2022-85 (REF. 1003240-43.2022.4.01.0000)

B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.003587/2022-01 AGRAVO DE INSTRUMENTO (202) 1011696-79.2022.4.01.0000 NUP: 00424.117998/2022-13 AGRAVANTE: HYPERMARCAS S/A, FAES FARMA S.A AGRAVADO: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL DECISAO: DEFIRO O PEDIDO DE ANTECIPACAO DA TUTELA RECURSAL FORMULADO NA INICIAL, PARA RESTABELECER A VIGENCIA DA PATENTE PI0108394-5 E SUSPENDER OS EFEITOS DO DESPACHO 16.3 DO INPI, ATE A REALIZACAO DA PROVA PERICIAL, VISANDO A APURACAO DA DEMORA SUPOSTAMENTE INJUSTIFICADA DO INPI DURANTE O RESPECTIVO PROCESSO DE CONCESSAO.

B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.004947/2022-84 NUP: 00407.013384/2022-71 (REF. 0118882-60.2022-1.00.0000) INTERESSADOS: EMS S/A DIVISAO HORTOLANDIA E OUTROS. SENTENCA: HOMOLOGADA A DESISTENCIA DOS AGRAVOS REGIMENTAIS DE HIPERA S/A E FAES FARMA S/A, TRANSITANDO EM JULGADO A DECISAO ANTERIOR QUE JULGOU PROCEDENTE A RECLAMACAO E RESTABELECEU OS EFEITOS DO DESPACHO 16.3 DO INPI.

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.2 NA RPI NO 2668 DE 22/02/2022 CONFORME DETERMINADO NO PROCESSO INPI NO 52402.004947/2022-84 NUP: 00407.013384/2022-71 (REF. 0118882-60.2022-1.00.0000) INTERESSADOS: EMS S/A DIVISAO HORTOLANDIA E OUTROS. SENTENCA: HOMOLOGADA A DESISTENCIA DOS AGRAVOS REGIMENTAIS DE HIPERA S/A E FAES FARMA S/A, TRANSITANDO EM JULGADO A DECISAO ANTERIOR QUE JULGOU PROCEDENTE A RECLAMACAO E RESTABELECEU OS EFEITOS DO DESPACHO 16.3 DO INPI.

B21I Extinguishment of a patent or of a certificate of addition of invention: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 21.9 NA RPI NO 2668 DE 22/02/2022 CONFORME DETERMINADO NO PROCESSO INPI NO 52402.004947/2022-84 NUP: 00407.013384/2022-71 (REF. 0118882-60.2022-1.00.0000) INTERESSADOS: EMS S/A DIVISAO HORTOLANDIA E OUTROS. SENTENCA: HOMOLOGADA A DESISTENCIA DOS AGRAVOS REGIMENTAIS DE HIPERA S/A E FAES FARMA S/A, TRANSITANDO EM JULGADO A DECISAO ANTERIOR QUE JULGOU PROCEDENTE A RECLAMACAO E RESTABELECEU OS EFEITOS DO DESPACHO 16.3 DO INPI.

B19A Notification of judicial decision: notification of judicial decision

Free format text: PROCESSO INPI NO 52402.001366/2022-91 NUP: 00848.001633/2023-78 (REF. 00424.035864/2022-85) INTERESSADOS: PHARMACIA AND UPJOHN COMPANY E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI. 2 SENTENCA:"...MANIFESTO-ME NO SENTIDO DE A LIMINAR/TUTELA PROVISORIA ANTERIORMENTE CONCEDIDA FOI CASSADA, NAO ESTANDO MAIS A ENTIDADE REPRESENTADA COMPELIDA A CUMPRIR, EM RAZAO DESTE PROCESSO, A OBRIGACAO ANTERIORMENTE DETERMINADA."DIANTE DO EXPOSTO, DEVE SER RESTABELECIDO O DESPACHO 16.3, QUE ALTEROU O PRAZO DO VIGENCIA DA PATENTE DE ACORDO COM A DECISAO DA ADI 5529.